Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
Dey, Joyoti, Deckwerth, Thomas L, Kerwin, William S, Casalini, Joseph R, Merrell, Angela J, Grenley, Marc O, Burns, Connor, Ditzler, Sally H, Dixon, Chantel P, Beirne, Emily, Gillespie, Kate C, Kleinman, Edward F, Klinghoffer, Richard A
Published in Scientific reports (21.12.2017)
Published in Scientific reports (21.12.2017)
Get full text
Journal Article